Anacor Pharmaceutical

About:

Anacor Pharmaceutical is a biopharmaceutical company developing small-molecule therapeutics from its boron chemistry platform.

Website: http://www.anacor.com

Top Investors: Hercules Capital, Venrock, Rho Capital Partners, GSK, Aberdare Ventures

Description:

Anacor Pharmaceuticals is a biopharmaceutical company that engages in developing small-molecule therapeutics from its boron chemistry platform. It focuses on developing topical applications of its compounds to treat fungal, bacterial, and inflammatory diseases. The company’s primary product candidate, AN2690, is a novel topical antifungal for the treatment of toenail onychomycosis, a fungal infection of the nail and nail bed. It is also developing AN2728, an anti-inflammatory product candidate for the treatment of psoriasis; AN0128, a product candidate that has antibiotic and anti-inflammatory properties; and AN2718, which is in preclinical development for the topical treatment of vaginal candidiasis and tineapedis.

Total Funding Amount:

$448M

Estimated Revenue Range:

$50M to $100M

Headquarters Location:

Palo Alto, California, United States

Founded Date:

2000-01-01

Contact Email:

info(AT)anacor.com

Founders:

Lucy Shapiro, Stephen Benkovic

Number of Employees:

51-100

Last Funding Date:

2016-04-06

IPO Status:

Delisted

© 2025 bioDAO.ai